| Dr Edward M Deutscher, MD | |
|
1301 2nd Ave Sw, Largo, FL 33770-3120 | |
| (727) 584-7706 | |
| (727) 581-4822 |
| Full Name | Dr Edward M Deutscher |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1301 2nd Ave Sw, Largo, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871521021 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | ME39550 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward M Deutscher, MD 1301 2nd Ave Sw, Largo, FL 33770-3120 Ph: (727) 584-7706 | Dr Edward M Deutscher, MD 1301 2nd Ave Sw, Largo, FL 33770-3120 Ph: (727) 584-7706 |
News Archive
CNA recognizes the importance of patient/resident safety and risk management in the evolving world of healthcare. As one of the nation's leading providers of professional liability insurance for healthcare providers and organizations, CNA HealthPro recently published a risk management toolkit, "Special Resource: Protecting Residents, Reducing Liability Exposure - An Aging Services Resource from CNA HealthPro," which offers guidance on clinical, operational, and strategic subjects of concern to aging services providers.
Newborn infant girls have better outcomes than their male counterparts due to an innate genetic advantage in responding to acute infections, according to new research from RCSI.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Feeding human breast milk to very-low-birth-weight infants greatly reduces risk for sepsis and significantly lowers associated neonatal intensive care unit (NICU) costs, according to a study by Rush University Medical Center researchers.
Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today the publication of new data in the journal Nature Medicine describing the role of the tumor suppressor miRNA, miR-34, in preventing cancer stem cell development. The published results reveal that miR-34 is commonly down-regulated in prostate cancer stem cells and that this down-regulation is essential for cancer stem cell viability.
› Verified 1 days ago
Philip Lee Shettle, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 13113 66th St, Largo, FL 33773 Phone: 727-674-2500 Fax: 727-674-2550 | |
Stacia H Goldey, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 148 13th St Sw, Largo, FL 33770 Phone: 727-581-8706 Fax: 727-588-2447 | |
Dr. Bradley Philip Oneill, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 148 13th St Sw, Largo, FL 33770 Phone: 727-581-8706 Fax: 727-588-2447 | |
Dr. Winston T Cope, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 148 13th St Sw, Largo, FL 33770 Phone: 727-642-0301 | |
Siddarth Rathi, MD, MBA Ophthalmology Medicare: Medicare Enrolled Practice Location: 148 13th St Sw, Largo, FL 33770 Phone: 727-581-8706 Fax: 727-588-2447 | |
Dr. Frank Seidl, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2770 E Bay Dr, Largo, FL 33771 Phone: 727-530-1425 | |
Robert Davis, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 148 13th St Sw, Largo, FL 33770 Phone: 727-581-8706 |